Objective ambulatory activity during daily living has not been characterized for people with Parkinson disease prior to initiation of dopaminergic medication. Our goal was to characterize ambulatory activity based on average daily step count and examine determinants of step count in nonexercising people with de novo Parkinson disease. 
INTRODUCTION
H abitual low ambulatory activity has been characterized as an early problem for people with Parkinson disease (PD). 1−5 People with PD have low self-reported physical activity 5 and objective levels of ambulatory activity 6 compared with healthy people of similar age and spend the vast majority of waking time (>90%) in sedentary to low-intensity activities. 2, 6, 7 Importantly, ambulatory activity declines as the disease progresses, illustrated in both cross-sectional 6 and
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In people with PD who take dopaminergic medications, low ambulatory activity is of clinical concern because lower activity is associated with gait dysfunction 3 and greater selfreported disability. 5 Reduced average daily step count, compared to healthy controls, is observed soon after the onset of PD medical treatment. 6 As such, low ambulatory activity could be one of the earliest indicators of functional decline for people with PD. However, expected daily step counts for people with de novo PD are currently unknown.
If ambulatory activity is an indicator of early functional decline, it is reasonable to expect that step counts may be low in de novo PD. It would be important to identify such an early indicator of functional decline, since most motor signs of PD are recognized only after significant (60%-80%) death of dopaminergic neurons has occurred. 8, 9 Examining ambulatory activity early in the disease process may provide evidence to recommend early exercise and physical activity intervention. Thus, measuring and understanding the influence of daily step count in de novo PD can provide important information to clinicians and people seeking to mitigate later functional ramifications, while still in the early disease process.
To better understand the problem of low step count in people with de novo PD, identification of factors that explain step count variability is essential. A number of factors have been associated with low levels of ambulatory and other types of physical activity in people with and without PD. Variables associated with low activity levels in the general population include older age, 10−12 female sex, 13 low education level, 13, 14 low cardiorespiratory fitness, 15 and high body mass index (BMI). 16−18 For people with PD on dopaminergic medications, both motor and nonmotor symptoms are linked with ambulatory activity. 1, 3, 5 Lord and colleagues 6 (n = 98) reported people with PD (H&Y I-III) on dopaminergic medications walked on average 5423 steps per day compared with a healthy comparison group (n = 97) that averaged 7816 steps per day, over a 7-day period. In addition, fatigue, 19, 20 sleep problems, 21 and fear of falling 22 have been associated with reduced ambulatory activity in other populations and are also characteristics common to people with PD early in the disease process. 23−25 However, there is little knowledge of factors associated with ambulatory activity in people with de novo PD.
Characterizing average daily step count prior to initiation of dopaminergic medications will add knowledge to the current understanding of ambulatory activity decline with PD progression in the absence of the negative or positive impact of medication. Identifying explanatory variables for step count can provide potential intervention targets to improve ambulatory activity early in the disease process and mitigate negative long-term functional consequences for people with PD. Therefore, the purposes of this study were to (1) characterize ambulatory activity based on average daily step count and (2) examine possible determinants of step count in people with de novo PD who did not perform regular exercise and were recruited to participate in an exercise intervention trial.
METHODS
This study reports baseline data from the Exploratory Study of Different Doses of Endurance Exercise in People with Parkinson Disease (SPARX; NCT01506479), a randomized controlled trial examining the effects of different doses of endurance exercise in people with de novo PD. 26 The study protocol, with detailed inclusion and exclusion criteria, has been previously reported. 26 Briefly, PD was diagnosed by a neurologist, with inclusion criteria being that participants met the UK Brain Bank criteria for idiopathic PD, 27 Hoehn and Yahr (H&Y) scale 28 
Participants
A total of 128 participants with PD were recruited from the Chicago, Denver, and Pittsburgh metropolitan areas with ambulatory activity data obtained from 113 participants (64.3 ± 8.6 years). Fifty-six percent (n = 63) of the included sample were men and MDS-UPDRS motor score was 21.1 ± 8.8, indicating a mild level of motor symptoms (Table 1) . 30 Baseline activity monitor data were missing from 15 participants due to data collection errors (n = 9), noncompliance for wear time (n = 4), or withdrawal prior to data collection (n = 2).
Ambulatory Activity Monitoring
Ambulatory activity was monitored during waking hours for all participants over a 10-day period after screening, but before randomization, using waist-worn accelerometer (ActiGraph GT3X [+ and BT]; Actigraph, Pensacola, Florida). Both accelerometer models included the same 3-axis microelectromechanical system accelerometer, with the GT3X-BT having blue-tooth technology capabilities (note: blue-tooth capabilities of the devices were not used in this study). The accelerometers were selected on the basis of the established validity (moderate to high) and reliability for estimating daily step count in free-living conditions 31−33 and sensitivity to measurement of steps in people with PD. 2, 34 Acceleration data were sampled by a 12-bit analog to digital converter at 60 Hz and processed using commercially available software (ActiLife 5/6; Actigraph). A device firmware algorithm screened out the accelerometer baseline noise level to help accurately accumulate the steps per epoch, (18, 19, 20 , and 21) were erroneously excluded from the tool prior to data collection. For the subscales that required a missing item (physical and cognitive), we took the average of the existing items as the imputed value for the missing item before summing the items to create the subscales. The total MFIS score was calculated by summing the subscales.
with epochs being the blocks of time (60 seconds in our protocol) in which steps were averaged. An inclinometer feature indicated device positioning, for identification of nonwear periods.
The accelerometer data were reduced, selecting valid days to include in the analysis as those with more than 10 hours of valid wear time and a maximum of 90 minutes of nonwear. 35 At least 3-week days and one weekend day of valid wear time were required for participant inclusion in the analysis (4 participants excluded for noncompliance with wear time).
Step count (number of steps per day) was based on the 60-second epochs of accelerometer data collected on the vertical axis and average daily step count for each valid day was calculated for the total wear period (ie, weekdays and weekend days).
Activity count (total number of accelerometer vector count) was also determined in 60-second epochs and averaged for the total wear period, to characterize the total volume of daily physical activity. 12 Activity count represents the sum of the accelerometer vectors in all 3 planes and reflects the frequency and intensity of movement, unlike the step count, which reflects steps based on vertical axis acceleration.
Candidate Explanatory Variables
Six groups of candidate explanatory variables for average steps per day were defined, using specific measures within each group: (1) demographics/anthropometrics, (2) PD characteristics, (3) motor symptom severity, (4) nonmotor and
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Demographics and Anthropometrics
Age, 10 sex, 13 education level, 14 and BMI 16 were included as candidate demographic/anthropometric variables accounting for variation in ambulatory activity, as these factors are associated with physical activity in the general population.
Disease Characteristics
Time since PD diagnosis was selected as a candidate variable explaining ambulatory activity, as it has been suggested that ambulatory activity declines over time with PD. 3 In addition, motor subtype (tremor dominant or postural instability gait disorder [PIGD]) was entered as a candidate variable since the PIGD subtype may be more closely linked to ambulatory activity than the TD subtype. Tremor dominant and PIGD ratio scores were derived from the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) as described previously.
36
Motor Symptom Severity H&Y 37 scores were determined for each participant and the MDS-UPDRS 38 was administered by movement disorder neurologists to assess impairment and severity of PD symptoms. The MDS-UPDRS has 4 subscales: I-Non-motor Aspects of Experiences of Daily Living (13 items), II-Motor Aspects of Experiences of Daily Living (13 items), IIIMotor Examination (33 items), and IV-Motor Complications (6 items). 38 A higher score indicates more advanced disease state. The Motor Complication (IV) section relates to the effects of dopaminergic therapy; participants were not undergoing dopaminergic medications, thus this section score was not included in the analysis. Subscales II and III of the MDS-UPDRS were individually used as candidate explanatory variables representing motor symptom severity. The MDS-UPDRS was chosen over the Unified Parkinson Disease Rating Scale (UPDRS) as a potential predictor of ambulatory activity in de novo PD, as the MDS-UPDRS places greater emphasis of capturing very mild disease impairments, along with the presence of a broader range of motor and nonmotor disabilities.
38

Nonmotor and Behavioral Characteristics
Subscale I (Nonmotor Aspects of Experiences of Daily Living) of the MDS-UPDRS was used as a candidate variable representing overall nonmotor symptom severity. Participants also completed the Modified Fatigue Impact Scale, 39 Epworth Sleepiness Scale, 40 and Parkinson Disease Sleep Scale-2 41 to evaluate levels of fatigue and sleep. The Modified Fatigue Impact Scale assesses the effect of fatigue on physical, cognitive, and psychosocial function. The Epworth Sleepiness Scale focuses on daytime sleepiness. The Parkinson Disease Sleep Scale-2 focuses on nocturnal sleep impairment. The 3 questionnaires are validated and recommended for assessing participants with PD. 39, 42 Fear/worry of falling was assessed using Item 9 of the PDQ-39, which asks the participant to report how often in the past month he or she "felt frightened or worried about falling." This item is rated on a 5-point scale (1 "never," 2 "occasionally," 3 "sometime," 4 "often," 5 "always"). Participants were categorized dichotomously as either having none (1) or any (2-5) frequency of feeling frightened or worried about falling.
Comorbidities
The presence of 4 comorbidity candidate variables was examined: total number of comorbidities, osteoarthritis, cardiovascular (eg, hypertension, coronary artery disease), and pulmonary conditions (eg, asthma, sleep apnea). These measures were captured using a general medical history form at the initial study visit, which included all significant medical history items self-reported to the clinician by the participant. Although participants with disorders of sufficient severity to interfere with ability to perform endurance exercise were excluded from the SPARX study, the presence of osteoarthritis, cardiovascular, and pulmonary medical conditions was not specifically excluded. 26 
Cardiorespiratory Fitness
As part of the screening for the SPARX trial, each participant completed a maximal graded exercise test including measurement ofVO 2 peak by indirect calorimetry under supervision of a clinician. 43, 44 The test was performed at the walking speed that elicited a heart rate that was 70% of age-predicted maximal heart rate for the participant. If the participant was on β-blocker medication at the time of the test, the selected walking speed was one that elicited a rate of perceived exertion of 4 on a 0-10 Rating of Perceived Exertion Scale.
45V O 2 peak was quantified as the greatest rate of oxygen consumption per minute (normalized by body mass and sampled in 30-second intervals) for the exercise test period.
Statistical Analysis
Descriptive statistics were calculated for all candidate explanatory variables for the total sample and by sex. Univariate associations between average daily step count and each candidate explanatory variable were tested using correlations for continuous variables and ANOVA (or 2-sample t test) for categorical variables. Multiple linear regression was used to explore factors associated with ambulatory activity, measured as average daily step count. The square root transformation was applied to average daily step count for all modeling due to the skewness of the data. Multiple linear regression was first performed within each grouping of variables using those significant at P ≤ 0.2: (1) demographics/anthropometrics, (2) disease characteristics, (3) motor symptom severity, (4) nonmotor and behavioral characteristics, (5) comorbidities, and (6) cardiorespiratory fitness. Variables maintaining associations with step count of P ≤ 0.2 within each group were combined in an overall model, where backward elimination was applied (α = 0.10). Data are presented as mean ± SD, unless otherwise stated. All analyses were controlled for study site location (3 sites) and were conducted using SAS Enterprise Guide version 6.1 (Cary, North Carolina).
RESULTS
Mean accelerometer wear time was 13.3 ± 1.6 hours per day with an average of 5362 ± 2890 steps per day and 345 870 ± 141 796 activity counts per day (Table 2) . 46 Eight
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variables were identified as having a P value of ≤ 0.2 in subgroup analyses and were included in the full model (Table  3) . After backward elimination, only 5 variables remained significant at P ≤ 0.1. Significant explanatory variables in the final model explained a total of 24% of the variability in average daily step count. These includedVO 2 peak (10%), fear/worry of falling (5%), MDS-UPDRS motor examination score (4%), time since PD diagnosis (3%), and the presence of a cardiovascular condition (2%). Higher step count was associated with higherVO 2 peak, no fear or worry of falling, lower MDS-UPDRS motor examination score, more recent PD diagnosis, and presence of cardiovascular conditions (ie, greater activity with a cardiovascular condition).
DISCUSSION
The primary objective of our study was to characterize ambulatory activity, based on daily step count, in nonexercising individuals with de novo PD. Average daily step count for our sample was 5362 ± 2890 steps per day. Our result was similar to the study by Lord and colleagues, 6 which reported people with PD (H&Y I-III; n = 98) walked on average 5423 steps per day. In addition, Benka Wallen and colleagues 2 reported that people with PD (H&Y II-III, n = 95) had an average step count of 4765 steps per day. Although there is no commonly agreed-upon value of daily step count to distinguish physically active versus physically inactive adults, it has been suggested that 5000 steps per day are associated with sedentary lifestyle in the general population of adults 46 and the mean for our sample is at the low end of the "low active" category (5000-7499 steps per day). 47, 48 In addition, accelerometer-based step a Variables at P ≤ 0.2 for univariate and subgroup models were considered for the full model. All variables in the full model were considered for the final model at the start. After running the backward elimination model, only the variables significant at the P ≤ 0.1 were selected for the final model.
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The daily step count for nonexercising people with de novo PD highlights the importance of identifying barriers to ambulatory activity and considering interventions (eg, exercise and physical activity behavior modification) immediately after diagnosis of PD if the goal is to mitigate future negative health consequences of low ambulatory activity. This is especially important because while higher doses of dopaminergic medication are not associated with greater ambulatory activity, 1 the effects of exercise and medication are complementary. 51 However, further research is warranted to determine how step count in PD relates to healthy cohorts (exercising and/or nonexercising) and whether increasing daily step count would reduce the symptoms of the disease or if reduced step count is a beneficial compensatory response to the disease. For example, if reduced step count is a compensation to conserve energy, it is not known if any possible energy conservation would outweigh the known negative consequences of a sedentary lifestyle. 52, 53 The second aim was to identify explanatory factors of daily step count in nonexercising people with de novo PD. We found higher step count in our sample to be associated with higher cardiorespiratory fitness, no fear or worry of falling, lower MDS-UPDRS motor examination score, more recent PD diagnosis, and presence of cardiovascular conditions (ie, greater activity with a cardiovascular condition). Cardiorespiratory fitness and fear/worry of falling explained the greatest amounts of the variability in average daily step count at 10% and 5%, respectively. These explanatory factors are potential therapeutic targets for future intervention trials, which is particularly important in de novo PD because clinical motor and nonmotor symptoms are relatively mild prior to onset of dopaminergic medications.
Despite being mildly affected by MDS-UPDRS score, time since diagnosis and motor symptom severity accounted for a combined total of 7% of the variability in average daily step count in our final model. Lower motor symptom severity and less time since diagnosis of PD were associated with higher average daily step count. Ambulatory activity has previously been associated with PD motor symptoms, with higher motor severity linked to lower activity in both cross-sectional 6 and longitudinal data. 3 For example, Cavanaugh and colleagues 3 followed people with PD (H&Y 1-4 at initial enrollment; on dopaminergic medication) period and observed that average daily step count decreased by 1945 steps and MDS-UPDRS motor examination scores worsened by 7.4 points over a 2-year period. Our results add to this knowledge by establishing that even mild motor symptoms are linked to lower ambulatory activity.
Of note, the presence of a cardiovascular health condition was associated with a greater average daily step count, which appears to be counterintuitive. Physical activity and exercise are common recommendations from health care professionals, with strong evidence for cardiovascular protective effects. For example, people with coronary artery disease have a 16% reduced risk of mortality for every increased hour of physical activity (defined by the study as ≥100 counts per minute). 54 It is well established that walking programs for patients with cardiovascular conditions are effective at increasing ambulatory activity. 55−58 Thus, it is possible that participants who were aware of their cardiovascular disease might have intentionally increased their ambulatory activity due to recommendations from their physicians. Future study is warranted to examine the relationship between cardiovascular comorbidity and average daily step count.
The association between fear/worry of falling and lower ambulatory activity is consistent with literature for other populations. For example, 41% of older adults who receive home care services report intentional activity restriction due to fear of falling. 22 Our cross-sectional analysis cannot determine if low daily step count was a result of fear/worry of falling. However, the relationship between ambulatory activity and fear/worry of falling is concerning for people with PD, as there is potential for negative health consequences. For example, if fear/worry of falling leads to decreased activity, the lower activity could lead to declines in muscle function, physical deconditioning, and other physiologic functions, which could lead to greater risk of falls. 59 The relatively strong association ofVO 2 peak with average daily step count is important, as it suggests that maintaining or improving cardiorespiratory fitness might be an effective strategy to maintain healthy levels of ambulatory activity, or that increasing ambulatory activity could improve cardiorespiratory fitness. This is consistent with data from a study examining the general population, which found a link between low physical activity and low cardiorespiratory fitness. 60 There is emerging evidence that exercise training can be used to improve cardiorespiratory fitness in people with PD, 61,62 although there is not a clear link between exercise training and ambulatory activity in this population. Findings from the longitudinal SPARX parent trial 26 will help elucidate the relationship between cardiorespiratory fitness and ambulatory activity, and the influence of various doses of exercise. Furthermore, given the association of step count with cardiorespiratory fitness, it is important to determine whether there are underlying physiologic changes with PD that compromise overall ambulatory activity very early in the disease process.
Limitations
The final model in this study explained 24% of the variability in daily step count, indicating that further research is needed to examine other factors explaining ambulatory activity in this population. An exclusion criterion for the SPARX trial was engagement in "moderate or vigorous endurance exercise, defined as >2 days/week for at least the past four months." While no participant was excluded during screening based on the exercise criterion, 28.5% of people who were phone screened related that they exercised regularly at a level that produced sweat. In contrast, it is also possible that very sedentary people with PD would not choose to participate in an "exercise study." Thus, the results of this study cannot be generalized to all people with de novo PD. Also, depression was an exclusion criterion. No individuals were excluded on the basis of the cutoff of Beck Depression Inventory 29 scores greater than 16; however, it is possible that the participants with depression self-identified during the telephone prescreen and were not enrolled. Therefore, the PA level of the sample might have been lowered if depression was not an exclusion criterion. 63 One of the identified factors associated with step count was fear/worry of falling, which was grouped with nonmotor symptoms, as it was a patient-reported perception. As such, we were not able to examine the association of actual falls and step count, which should be examined in a future study. 64 Finally, the cross-sectional nature of the study cannot assess causal relationships between daily step count and the associated factors.
CONCLUSIONS
Step count in people with de novo PD who were not regular exercisers approached sedentary lifestyle levels. Higher step count was associated with higher cardiorespiratory fitness and no fear/worry of falling. Further study is warranted for elucidating factors that explain ambulatory activity, particularly cardiorespiratory fitness and fear/worry of falling. Clinicians should consider the costs and benefits of interventions such as exercise and activity behavior modification immediately after diagnosis of PD to attenuate the potential adverse health consequences of chronically low ambulatory activity.
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